Autologous bone is a finite resource and harvesting is associated with significant morbidity. This study investigated the safety and efficacy of allogeneic mesenchymal progenitor cells (MPCs) delivered via a calcium phosphate carrier to stimulate bone growth in spinal fusion compared to autograft control in an ovine model. MPCs promote early development of spinal fusion equivalent to autologous bone graft in this ovine model. Given the potential for significant clinical problems with autologous grafting consideration must be given to using MPCs in this setting
